Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hematology · Light-Chain (AL) Amyloidosis

Am I Eligible for a Stem Cell Transplant for AL Amyloidosis?

At a Glance

Eligibility for an autologous stem cell transplant in AL amyloidosis is based on overall organ function and physical fitness, not one pass/fail test. Heart involvement is especially important, and induction treatment may improve organ function enough for a later transplant evaluation.

Determining if your body is healthy enough for an autologous stem cell transplant (ASCT) is one of the most complex evaluations your care team will conduct. Because the high-dose chemotherapy used in a transplant places immense physical strain on the body, doctors must carefully assess your ability to tolerate the procedure and recover safely.

There is no single universal test or “pass/fail” checklist. Instead, your doctors look at a combination of your organ function, your blood pressure, and your overall physical fitness [1]. Assessment thresholds can vary depending on the hospital’s specific protocols and the exact laboratory tests used, so one abnormal number does not automatically exclude you. Because this process is highly individualized, it is often reasonable to seek an evaluation at a specialized amyloidosis center.

Heart Function and Blood Pressure

For patients with AL amyloidosis, cardiac involvement is often the dominant factor in determining transplant risk [2]. Even if you do not feel heart-related symptoms, amyloid proteins can stiffen the heart muscle.

  • Cardiac Biomarkers: Blood tests measuring NT-proBNP (or BNP) and Troponin reveal how much stress your heart muscle is experiencing. Doctors use these to stage the disease and estimate risk [3]. For example, in some risk models, an NT-proBNP level above 2,000 pg/mL indicates substantially higher transplant risk [2]. Conversely, a Troponin T level below 0.06 ng/mL is sometimes used as a baseline safety marker [4]. However, these are just examples used in specific protocols, not strict universal cutoffs, and must be interpreted alongside your kidney function and other tests.
  • Echocardiogram (Heart Ultrasound): Doctors evaluate your heart’s pumping function, filling pressures, and wall thickness. A wall (septal) thickness greater than 15 millimeters is associated with higher risk [5], but this is evaluated together with overall heart function. Doctors also measure Global Longitudinal Strain (GLS), which shows how effectively the heart muscle fibers squeeze and pull, helping to categorize your specific risk level [3].
  • Blood Pressure (Hemodynamics): You need cardiovascular reserve to safely undergo stem cell collection and transplantation. While some historical guidelines suggested a resting systolic blood pressure consistently above 90 mmHg as a safety marker [4], doctors are primarily looking for stability. Severe drops in blood pressure when you stand up (orthostatic hypotension) or persistent dizziness can complicate the transplant [6]. (Note: Never adjust your blood pressure medications or fluid intake without your team’s direct instruction).

Kidney Function and Protein Levels

Your kidneys filter waste from your blood, which can affect how certain chemotherapy drugs are cleared from your body.

  • eGFR and Creatinine: These values estimate how well your kidneys are filtering blood. While historically doctors used a serum creatinine level of 1.7 mg/dL or lower as a general safety threshold [4], modern evaluations are more nuanced. Having reduced kidney function (such as an eGFR below 40 or 45) does not automatically disqualify you, but it does significantly increase the risk of acute kidney injury and the potential need for temporary or permanent dialysis during recovery [7][8].
  • Serum Albumin: This is a vital protein in your blood. Low albumin (for instance, under 2.5 or 3.0 g/dL) is associated with a higher risk of fluid overload and kidney complications during transplant [8][9]. In amyloidosis, low albumin is frequently caused by the kidneys leaking protein into the urine, but it can also be due to liver involvement, malnutrition, inflammation, or fluid status.

Physical Fitness, Age, and Other Factors

  • Performance Status: Doctors use tools like the ECOG scale to rate your activity level, self-care ability, and how much time you spend in a chair or bed. An ECOG score of 0 or 1 (meaning you are fully active or restricted only in physically strenuous activity) is ideal. A score of 2 or 3 (meaning you need more rest and assistance) substantially increases predicted transplant risks [1].
  • Age Considerations: Chronological age alone is no longer an automatic exclusion. Highly experienced amyloidosis centers have performed transplants on carefully selected, highly fit patients in their late 60s and 70s [10][11]. However, risk generally rises with age and frailty, so older patients undergo rigorous individualized screening.
  • Additional Assessments: Beyond the heart and kidneys, your team will also evaluate your lung function, liver health, nutritional status, any active infections, and your caregiver support system at home.

The Number and Severity of Organs Involved

Historically, if AL amyloidosis affected three or more major organs, a transplant was often considered too dangerous. Today, while multiorgan disease still increases overall risk and requires careful consideration, research has shown that the severity of the organ damage—particularly severe cardiac involvement—is often a stronger predictor of transplant safety than the simple count of involved organs [2][12].

What If You Aren’t Eligible Right Now?

If your doctors determine that a transplant is currently too risky, it does not mean you have no options. Many patients first receive induction therapy—a regimen of targeted medications designed to suppress or eradicate the abnormal plasma cells in your bone marrow. This stops the production of the abnormal light chains that form amyloid deposits.

It is important to understand the difference between a hematologic response (when blood tests show the abnormal proteins are reduced) and an organ response (when the function of organs like the heart or kidneys actually improves). Hematologic responses can happen quickly, but organ responses are variable and take much more time. If induction therapy eventually improves your organ function, you may be re-evaluated and become a candidate for a delayed (deferred) stem cell transplant [13][14].


⚠️ Important Safety Note

While you are being evaluated for treatment, do not wait for your next appointment if you experience new or worsening symptoms. Contact your medical team immediately or seek emergency care if you develop new fainting spells, severe shortness of breath, chest pain, rapid swelling or weight gain, markedly reduced urine output, or persistent dizziness.

Common questions in this guide

How do doctors determine whether I am eligible for ASCT with AL amyloidosis?
Your team usually reviews heart biomarkers such as NT-proBNP and troponin, an echocardiogram, blood-pressure stability, kidney filtration, creatinine, and albumin. They also consider your activity level, age and frailty, lung and liver health, nutrition, infections, organ involvement, and home support. There is no single universal cutoff, so results are interpreted together.
What heart tests affect stem cell transplant eligibility in AL amyloidosis?
Doctors assess cardiac biomarkers, an echocardiogram, heart-wall thickness, pumping and filling function, and global longitudinal strain. They also look for stable blood pressure and symptoms such as fainting or dizziness. Severe cardiac involvement often has the greatest effect on transplant risk, but the decision is individualized.
Can kidney problems prevent an autologous stem cell transplant?
Reduced kidney function or low albumin can increase the risk of kidney injury, fluid overload, and dialysis during recovery, but they do not always make transplant impossible. Doctors consider eGFR, creatinine, albumin, other organ function, and the chemotherapy plan together. Your team can estimate your personal risk and adjust treatment when appropriate.
Does age or involvement of several organs rule out an AL amyloidosis transplant?
Age alone is not an automatic exclusion, although risk generally increases with age and frailty. Having multiple organs involved also raises concern, but the severity of damage—especially to the heart—may matter more than the number of organs alone. Experienced amyloidosis centers assess each patient individually.
Can induction therapy make me eligible for ASCT later?
Possibly. Induction therapy aims to reduce abnormal light-chain production from plasma cells, while organ recovery may take longer than the blood-test response. If heart, kidney, or other organ function improves enough, your team may reassess you for a delayed transplant.
What happens if I am not eligible for a stem cell transplant right now?
Your doctors may recommend induction therapy or other targeted treatment to control the abnormal plasma cells and light chains. If your organ function improves, you may be reassessed for a delayed transplant. If transplant remains unsafe, your team can discuss alternative treatment pathways tailored to your disease and organ function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my Mayo cardiac stage, and how does the center interpret my specific NT-proBNP and Troponin levels regarding my personal transplant risk?
  2. 2.Based on my eGFR and albumin levels, what is my individual risk of needing dialysis if I go through with a transplant, and how would my chemotherapy dosing be adjusted?
  3. 3.What are the expected benefits versus the transplant-related mortality risks at this specific center for someone with my level of organ involvement?
  4. 4.If I am not a candidate right now, what specific markers would need to improve after induction therapy for me to be reconsidered for a deferred transplant?
  5. 5.If a transplant never becomes a safe option for me, what are the most effective alternative treatment pathways?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.

    Muchtar E, Dispenzieri A, Sanchorawala V, et al.

    Bone marrow transplantation 2025; (60(5)):595-602 doi:10.1038/s41409-025-02535-z.

    PMID: 39994333
  2. 2

    Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

    Al Saleh AS, Sidiqi MH, Muchtar E, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1520-1525 doi:10.1016/j.bbmt.2019.04.024.

    PMID: 31054986
  3. 3

    Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

    Pun SC, Landau HJ, Riedel ER, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(1)):64-70 doi:10.1016/j.echo.2017.08.017.

    PMID: 29111123
  4. 4

    Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.

    Gertz MA

    American journal of hematology 2020; (95(7)):848-860 doi:10.1002/ajh.25819.

    PMID: 32267020
  5. 5

    Prognostic significance of interventricular septal thickness in patients with AL amyloidosis.

    Cho H, Kim SJ, Shim CY, et al.

    Leukemia research 2017; (60()):36-43 doi:10.1016/j.leukres.2017.06.008.

    PMID: 28648672
  6. 6

    Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: A large retrospective case series study from a single institute in China.

    Yu XJ, Zhang X, Li DY, et al.

    Nephrology (Carlton, Vic.) 2020; (25(3)):202-211 doi:10.1111/nep.13633.

    PMID: 31301197
  7. 7

    Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

    Sidiqi MH, Nadiminti K, Al Saleh AS, et al.

    Bone marrow transplantation 2019; (54(11)):1775-1779 doi:10.1038/s41409-019-0524-2.

    PMID: 30962503
  8. 8

    The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.

    Leung N, Kumar SK, Glavey SV, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(8)):1284-9 doi:10.1093/ndt/gfv328.

    PMID: 26627634
  9. 9

    Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.

    Nader R, Zhen A, Angel-Korman A, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(7)):1281-1288 doi:10.1093/ndt/gfab189.

    PMID: 34043009
  10. 10

    Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

    Hassan H, Verma K, Ferri G, et al.

    Transplantation and cellular therapy 2022; (28(11)):761.e1-761.e7 doi:10.1016/j.jtct.2022.08.007.

    PMID: 35970300
  11. 11

    Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75.

    Sidiqi MH, Aljama MA, Muchtar E, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(10)):2157-2159 doi:10.1016/j.bbmt.2018.06.017.

    PMID: 29933071
  12. 12

    Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

    Afrough A, Saliba RM, Hamdi A, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015; (21(8)):1413-7.

    PMID: 25842049
  13. 13

    Deferred autologous stem cell transplantation in systemic AL amyloidosis.

    Manwani R, Hegenbart U, Mahmood S, et al.

    Blood cancer journal 2018; (8(11)):101 doi:10.1038/s41408-018-0137-9.

    PMID: 30397193
  14. 14

    From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.

    Muchtar E, Dispenzieri A, Buadi FK, et al.

    Blood advances 2025; (9(16)):4311-4316 doi:10.1182/bloodadvances.2025016586.

    PMID: 40590881

This page is for informational purposes only and does not constitute medical advice. Only your amyloidosis and transplant team can determine whether ASCT is safe for you based on your complete evaluation.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.